AGAgBiome Financial Model
Enterprise/Security Startup Financials (Free Excel Download)
AgBiome is a microbial-platform agtech company that discovers, develops, and commercialises biological crop protection products (and licences the platform across adjacent markets).
professionals from Deloitte
Used by professionals from
About this model
AgBiome discovers and commercialises biological crop-protection products from its Genesis microbial and genomics platform. Its flagship Howler fungicide addresses hundreds of crop-disease combinations, while the underlying platform also supports work in animal health, gene editing, and other adjacent markets.
Revenue comes from wholly owned product sales alongside joint ventures, licence fees, development milestones, and royalties. The company was supported by major ag and life-sciences investors and described a product-launch roadmap extending through 2030.
The model separates each product's launch ramp and gross margin from licence and royalty income by partner. It then links R&D, commercial spending, and cash runway to a probability-weighted pipeline valuation, with scenarios driven by market penetration, launch timing, new licensing agreements, and margin.
A turnkey financial model
Live formulas, no hardcoded values
Outputs are driven by live formulas, so the workbook updates from its assumptions instead of relying on hardcoded results.
All assumptions in one tab
Inputs are clearly marked in the Assumptions tab and separated from calculations, making it clear what to change and what to leave intact.
Statements always balancing
For integrated-statement models, the balance sheet, cash flow, and supporting schedules tie through properly.
Distinct schedules for clarity
Debt, working capital, taxes, and cash flow can get messy quickly. We group calculations in clear schedules, not across disconnected tabs.
No hidden macros or external links
There are no unexplained external workbook links or macros to undermine auditability or portability.
Changes flow through the model
Update a key driver and see the impact carry through the forecast, financing, and return outputs. We never use hardcoded numbers in formulas.
About AgBiome
agbiome.com
How to build a detailed financial model for AgBiome
A complete walkthrough of the business, drivers, and assumptions behind the downloadable AgBiome model - distilled from its pitch deck and publicly available information.
Product & value proposition
- Flagship product: Howler® - biological fungicide; works on 300+ crop-disease combinations (Botrytis, Rhizoctonia, Colletotrichum, Alternaria, Pythium, Phytophthora, Powdery/Downy Mildews, Sclerotinia).
- Platform: Genesis™ - proprietary genomic/informatics platform. 90,000+ fully-sequenced microbe strains (target 1M within 3 years); >300M unique genes; custom ML tools; can compare 100,000+ strains simultaneously or 45,000 genomes/second.
- Value proposition to growers: crop protection / higher yield, resistance management, reduced chemical residues, worker safety, sustainable production.
- Value proposition to consumers: natural/clean food, less chemical exposure, responsibly grown.
- Addresses 12/17 UN SDGs.
Market
- Global Biologicals market (primary): $1.4B (2020) → $14.4B (2030); CAGR ~26%
- Breakdown 2030: Biological Fungicides $5.8B, Insecticides & Nematicides $3.8B, Herbicides $3.3B, Biostimulants $1.5B.
- Market share shift: Biologicals = 2% of total crop protection market (~$60B conventional chemicals) in 2020; projected to reach 14% of ~$100B by 2030.
- Seven platform markets (TAM stated per market):
- Biologicals (wholly owned): $100B TAM
- Pharma (early licence/spinout): $500B TAM
- Synthetic Biology (early licence): $200B TAM
- Gene Editing (JV/early licence): $100B TAM
- Animal Health (early licence): $50B TAM
- Ag Traits / JV: $37B TAM
- Industrial Enzymes (early licence): $20B TAM
Revenue model
Four distinct business models layered on the same Genesis platform:
| Model | Who owns | Who commercialises | Value created |
|---|---|---|---|
| Wholly-owned | AgBiome | AgBiome | Revenue, profit, EV (e.g. Howler®, Theia) |
| JV / In-license | Partner | AgBiome | Market access, royalties, revenue, profit, EV |
| Early License | AgBiome | Partner | Early cash payment, royalties, technology leadership |
| Late License | AgBiome | Partner | Royalties, milestones, monetise pipeline |
- Named partnerships: LifeEdit (gene editing), GENECTIVE technology for plants (JV with TMG - Tropical Melhoramento & Genética), Elanco (animal health).
- Distribution: "Support of the largest U.S. ag retailers."
Traction & metrics
- Howler® first full year: "Generated significant revenue in its first full year, expected to grow in 2021 as a standalone product." - no dollar figure disclosed.
- Demo activity: ~240 product demos conducted.
- Retail support: Supported by the largest U.S. ag retailers.
- Field performance: Outperforming conventional products across multiple crops in key value drivers.
- Pipeline: Cumulative product launches: 1 (2020) → 3 (2021) → 7 (2022) → 8 (2023) → 10 (2024) → 11 (2025) → 12 (2026) → 16 (2027) → 23 (2028) → 28 (2029) → 30 (2030).
Competition / moat
- Moat: largest fully-sequenced microbe collection in the world; proprietary Genesis™ informatics platform; broad IP covering the fully-integrated process and products; ML-driven screening at massive scale.
- Market context: Less than 5% of crop protection market uses organic/biological alternatives today - early-mover advantage.
- Named competitive moves (all post-2019 M&A): Syngenta/Valagro, American Vanguard/Agrinos, Nutrien/Actagro, UPL/Arysta, Partners Group/Rovensa, Mitsui/Belchim - validating strategic appetite for biologicals platforms.
Team & funding ask / use of funds
- Leadership:
- Scott Uknes - Co-CEO; co-founder of multiple Ag companies (Ciba, Athenix)
- Eric Ward - Co-CEO; 30+ years in Ag and CEO experience (2Blades, Cropsolution, Novartis)
- Toni Bucci - Commercial Director / COO; 20+ years in Ag (BASF)
- Gerald Coward - CFO; 20+ years finance in Ag (Driscoll's)
- Rodrigo Sarria - Research; experienced R&D leader (Dow, BASF)
- Dan Tomso - Business Development; trait research leader (Athenix)
- Marijn Dekkers - Chairman; former CEO of Bayer and Thermo Fisher, Chairman Novalis LifeSciences
- John Flannery - Business Advisor; former CEO of GE
- Investors (existing): Polaris Partners, ARCH Venture Partners, Pontifax AgTech, Novalis LifeSciences, Fidelity, Novozymes, Bill & Melinda Gates Foundation, Syngenta, Bayer, UTIMCO, Innovtech Advisors.
Recommended financial model
- Archetype + why: Multi-revenue-stream AgBio operating model combining (a) product P&L (wholly-owned product sales), (b) milestone + royalty income schedule, and (c) R&D pipeline NPV optionality. This is an operating company, not an M&A or SPAC deck - use an operating forecast. The combination of product revenue and licence income is most comparable to a specialty pharma / agbio royalty + product model.
- Forecast horizon & granularity: 2021–2030 annual (aligns with the company's own 2030 product roadmap); quarterly detail for 2021–2023. Ten-year horizon is justified by the long product launch cadence and the market growth chart that extends to 2030.
- Key drivers & assumptions:
| Driver | Value / basis |
|---|---|
| Howler® 2021E revenue | $X - not disclosed; first full year with significant revenue |
| Pipeline product launches per year | Per slide 9 roadmap (1→3→7→8→10→11→12→16→23→28→30 cumulative) |
| 2030 global biologicals market | $14.4B |
| Early licence / milestone payments | Lump sums at signing + milestone triggers (e.g. IND filing, regulatory approval) |
| JV royalty income | Based on LifeEdit, GENECTIVE, Elanco partnerships |
- Scenarios (Base / Bull / Bear - which variables flex):
- Base: Howler grows ~50% YoY to 2025; 2 new product launches/yr on roadmap schedule; 1 early licence deal/yr; market share ~1.5% of biologicals market by 2030.
- Bull: Market adoption accelerates; 3 licence deals/yr; biologicals market reaches 20% of crop protection by 2030; AgBiome IPO/trade sale by 2025–2026.
- Bear: Howler market penetration slower (20% YoY); product launches delayed 1–2 years; no new licence deals in near-term; biologicals market grows to only $8B by 2030.
- Key flex variables: Howler revenue ramp, number and size of licensing deals, product launch timing, gross margin.
- Required sheets / outputs:
- Assumptions - all drivers, toggle switches for scenario
- Product Revenue Build - product-by-product launch schedule (from slide 9) × revenue ramp curve × blended ASP
- Licence / Royalty Income - early licence payments (cash at signing), milestone payments, royalty stream by partner
- P&L (Income Statement) - gross profit by segment, R&D, SG&A, EBITDA, net income
- Cash Flow & Runway - operating + investing CF; cumulative cash burn; runway to next raise
- Pipeline NPV - probability-weighted NPV of 30-product pipeline at 2030 (real option / rNPV)
- Market Sizing Cross-check - AgBiome revenue as % of biologicals market by year
- Valuation - DCF + comps (revenue multiple vs. listed agbio/biotech peers); M&A exit scenario
- Dashboard - KPIs: cumulative products launched, total revenue, EBITDA margin, cash, market share
Frequently asked
Is the AgBiome financial model free?+
Yes. The AgBiome model is a free Excel (.xlsx) download with live formulas. Sign up with your email and the workbook is yours to keep, review, and edit.
What's included in the model?+
A 5-year monthly forecast with P&L, cash flow and runway, valuation (exit multiple plus a DCF cross-check), MOIC/IRR returns, and unit economics, with live formulas throughout.
How was this model built?+
It was built from AgBiome's pitch deck and publicly available information, then structured to investment-banking standards as a fully editable Excel model.
Can I change the assumptions?+
Yes. You can change assumptions and the live formulas will recalculate in the downloadable Excel model.
Have more financial modelling questions? Contact us
Created by ex-finance professionals
Hey, I’m Alex and I created Finamodel.
Over my years in the finance industry I kept building the same models over and over again. Same structure, same assumptions, different logo. So I started building frameworks to turn them into clean, reusable templates.
Every model here is one I’d actually use for a client, and I personally vet each one before it goes up.
I’m not an expert in every industry, but I’ve built enough models to know what belongs in one. And when something is completely foreign to me, I reach out to my network for experts to work on our models with us.
Having a template library on hand cuts a first build from hours to minutes.
Need help finding your model? You’ll find me in the Finamodel app!
Other Enterprise/Security Startup Financial Models
Browse another startup in the same category.
Alation
Enterprise data intelligence platform - data catalog, governance, and metadata management for large organisations.
Archer SPAC
Archera
Cloud resource automation platform that continuously optimizes AWS commitment purchases, de-risks overcommitment, and automates FinOps workflows.
Ardoq
Cloud-native Enterprise Architecture (EA) SaaS platform that helps large enterprises navigate digital transformation through automated data collection, graph-based architecture modelling, and change impact analysis.
Ascend
Ascend.io is an enterprise big data automation platform ("Enterprise Intelligence Platform") that abstracts away the complexity of big data engineering so non-experts can build and run data pipelines.
Athennian
Cloud-based legal entity management system (EMS) uniting entity data with workflow and document automation.
Auditboard
Cloud-based integrated risk management platform connecting audit, risk, compliance, and ESG teams across the enterprise.
BoostUp
AI-powered contextual revenue intelligence platform that automatically extracts unstructured digital sales data to replace manual CRM entry and power forecasting
